Indian Journal of Pharmaceutical Sciences
Users online: 35
Scientific Publication of the Indian Pharmaceutical Association
Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size
The Journal Search Current Issue Archives Instructions Online submission Login  


 
SHORT COMMUNICATION
Year : 2006  |  Volume : 68  |  Issue : 5  |  Page : 656-657
Visible spectrophotometric methods for estimation of repaglinide in tablet formulation


1 B. N. P. G. College of Pharmacy, Udaipur-313 002, India
2 Department of Pharmaceutical Sciences, M. L. Sukhadia University, Udaipur-313 001, India

Date of Submission21-Jun-2005
Date of Decision05-Dec-2005
Date of Acceptance11-Oct-2006

Correspondence Address:
I Singhvi
Department of Pharmaceutical Sciences, M. L. Sukhadia University, Udaipur-313 001
India
Login to access the Email id


DOI: 10.4103/0250-474X.29641

Get Permissions

   Abstract 

Two simple, economical, precise and reproducible visible spectrophotometric methods have been developed for the estimation of repaglinide in tablet formulation. The developed methods are based on the formation of chloroform extractable complex of repaglinide with zincon and methylthymol blue in acidic medium. The extracted complex with zincon shows absorbance maxima at 533.0 nm and linearity in the concentration range of 50-250 g/ml. The extracted complex with methylthymol blue shows absorbance maxima at 427.0 nm and linearity in the concentration range of 100-500 g/ml. Results of analysis for both the methods were validated statistically and by recovery studies.



How to cite this article:
Goyal A, Singhvi I. Visible spectrophotometric methods for estimation of repaglinide in tablet formulation. Indian J Pharm Sci 2006;68:656-7

How to cite this URL:
Goyal A, Singhvi I. Visible spectrophotometric methods for estimation of repaglinide in tablet formulation. Indian J Pharm Sci [serial online] 2006 [cited 2014 Apr 16];68:656-7. Available from: http://www.ijpsonline.com/text.asp?2006/68/5/656/29641


Repaglinide, chemically, (S)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl] butyl]amino]-2-oxoethyl] benzoic acid, is a new nonsulphonyl urea oral hypoglycemic drug[1]. It is used in the treatment of type-2 diabetes mellitus[2]. It is official in USP[3] which describes liquid chromatographic method for its quantitation. Literature survey reveals HPLC[4],[5],[6] methods for the estimation of repaglinide from plasma and pharmaceutical formulation. The objective of the present investigation is to develop simple, accurate and economical spectrophotometric methods for the estimation of repaglinide in tablet formulation.

Thermospectronic UV1, UV/Vis double beam spectrophotometer with spectral bandwidth of 2 nm, wavelength accuracy of 0.5 and 1 cm matched quartz cells was used for analytical method development. All the chemicals and reagents used were of analytical grade. Zincon (2-[a-(2'-hydroxy-5'-sulfophenylazo)-bezylidine]hydrazino) benzoic acid monosodium salt, (Thomas Baker, Mumbai) reagent was prepared in acid phthalate buffer of pH 1.2 and methylthymol blue (CDH, New Delhi) reagent was prepared in acid phthalate buffer of pH 2.0. Both the reagents were prepared in double distilled water and extracted several times with chloroform so as to remove chloroform soluble impurities. Tablet formulation of repaglinide (Torrent, Ahemedabad) was procured from a local pharmacy. Standard solution of repaglinide was prepared by dissolving 100 mg in 100 ml of chloroform to give stock solution of concentration 1 mg/ml of drug.

For method I, in a series of 10 ml volumetric flasks, aliquots of standard drug solution (1 mg/ml) in chloroform were transferred and diluted with same so as to give several dilutions in concentration range of 50-250 g/ml of repaglinide. To 5 ml of each dilution taken in a separating funnel, 5 ml of zincon reagent was added. Reaction mixture was shaken gently for 5 min and allowed to stand for 5 min so as to separate aqueous and chloroform layer. The chloroform layer was separated out and absorbance maxima measured at 533.0 nm against a reagent blank. Calibration curve was plotted between concentration of repaglinide and measured absorbance.

For method II, in a series of 10 ml volumetric flasks, aliquots of standard drug solution (1 mg/ml) in chloroform were transferred and diluted with same so as to give several dilutions in concentration range of 100-500 g/ml of repaglinide. To 5 ml of each dilution taken in a separating funnel, 5 ml of methylthymol blue reagent was added. Reaction mixture was shaken gently for 5 min and allowed to stand for 5 min so as to separate aqueous and chloroform layer. The chloroform layer was separated out and absorbance measured at 427.0 nm against a reagent blank. Calibration curve was plotted between concentration of repaglinide and measured absorbance.

For analysis of tablet formulation, twenty tablets (1.0 mg and 2.0 mg) of repaglinide were weighed accurately and finely powdered. An accurately weighed portion of powdered sample, equivalent to 15 mg of repaglinide was taken in a 50 ml volumetric flask containing 25 ml of chloroform, sonicated for 20 minutes. The resultant was filtered through Whatman filter paper No. 41 into another 50 ml volumetric flask. The filter paper was washed several times with chloroform. The washings were added to the filtrate and the final volume was made up to the mark with chloroform.

For method I, 5 ml filtrate of the sample solution was diluted to 10 ml with chloroform and treated as per the procedure of the calibration curve. Amount of the drug present in sample was computed from respective calibration curve.

For method II, 5 ml filtrate of the sample solution was treated as per the procedure of the calibration curve. Amount of the drug present in sample was computed from respective calibration curve. The procedure of analysis from tablet formulation for both the methods was repeated five times with two different strengths of tablet formulation. Results of analysis are reported in [Table - 1].

Recovery studies were carried out for both the methods by the addition of known amount of standard drug solution of repaglinide to pre-analyzed tablet sample solution at three different concentration level. The resulting solutions were analyzed by proposed methods. The results of recovery studies were found to be satisfactory and are reported in [Table - 1].

These proposed methods were found to be simple, accurate, economical and rapid. Recovery studies were found close to 100 percent that indicates accuracy and precision of the proposed methods. Statistical analysis was carried out and the results of which were satisfactory. Standard deviation and relative standard deviation values were low that indicated reproducibility of the proposed methods. It was observed that excipients did not interfere in the determination of repaglinide. Hence these developed methods could be used for routine estimation of repaglinide in its tablet dosage forms.


   Acknowledgements Top


The authors are thankful to Torrent Laboratories Ltd., Ahmedabad, for providing gift sample of repaglinide.

 
   References Top

1.Budavari, S., Eds., In; The Merck Index, 12th Edn., Merck & Co., Inc., Whitehouse Station, NJ, 1996, 8308.   Back to cited text no. 1    
2.Reynolds, J.E.F., Martindale, 33rd Edn., The Complete Drug Reference, Pharmaceutical Press, London, 2002, 334.  Back to cited text no. 2    
3.United State Pharmacopoeia, Asian Edn., USP Convention Inc., Rockville MD, 2003, 1623.  Back to cited text no. 3    
4.Greischel, A., J. Chromatogr. , 1991, 568, 246.  Back to cited text no. 4    
5.Gandhimathi, M., Ravi, T.K. and Renu, S.K., Anal. Sci. , 2003, 19, 1675.  Back to cited text no. 5    
6.Krishna Reddy, K.V.S.R., MosesBabu, J., Mathad, V.T., Eswaraiah, S., Reddy, S.M., Dubey, P.K. and Vyas, K., J. Pharm. Biomed. Anal. , 2003, 32, 461.  Back to cited text no. 6    


    Tables

[Table - 1]

This article has been cited by
1 Development and validation of stability-indicating high-performance thin-layer chromatography method for estimation of repaglinide in bulk and in pharmaceutical formulation
P. S. Jain,M. K. Patel,S. J. Surana
Acta Chromatographica. 2013; 25(3): 531
[Pubmed]
2 Stability indicating RP-HPLC method for determination and validation of repaglinide in pharmaceutical dosage form
Sharma, M.C., Sharma, S.
International Journal of ChemTech Research. 2011; 3(1): 210-216
[Pubmed]
3 Determination of repaglinide in pharmaceutical formulations by RP-HPLC method
Prameela Rani, A., Bala Sekaran, C., Archana, N., Siva Teja, P., Aruna, B.
Journal of Applied Sciences Research. 2009; 5(10): 1500-1504
[Pubmed]
4 Estimation of repaglinide in bulk and tablet dosage forms by HPTLC method
Jiladia, M.A., Pandya, S.S.
International Journal of Pharmacy and Pharmaceutical Sciences. 2009; 1(Suppl 1): 141-144
[Pubmed]
5 Enzymatic method for the determination of Perindopril erbumine and Repaglinide in bulk and dosage forms
Prameela Rani, A., Bala Sekaran, C., Srilakshmi, Ch.
Biomedical and Pharmacology Journal. 2009; 2(1): 91-94
[Pubmed]
6 A comparative study of first-derivative spectrophotometry and column high-performance liquid chromatography applied to the determination of repaglinide in tablets and for dissolution testing
AlKhalidi, B.A., Shtaiwi, M., AlKhatib, H.S., Mohammad, M., Bustanji, Y.
Journal of AOAC International. 2008; 91(3): 530-535
[Pubmed]



 

Top
Print this article  Email this article
 
  Search
   
   Next article
   Previous article 
   Table of Contents
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (92 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
    Acknowledgements
    References
    Article Tables

 Article Access Statistics
    Viewed3924    
    Printed71    
    Emailed2    
    PDF Downloaded350    
    Comments [Add]    
    Cited by others 6    

Recommend this journal